News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

XDx, Inc.’s AlloMap(R) Considered ‘Medically Necessary’ by Aetna for Heart Transplant Recipients


3/8/2011 10:54:35 AM

BRISBANE, Calif.--(BUSINESS WIRE)--XDx, Inc., a molecular diagnostics company focused on noninvasive gene expression tests to monitor immune-mediated conditions, today announced that Aetna Inc., one of the nation's leading providers of health care insurance, has determined that AlloMap® is “medically necessary” for monitoring rejection in heart transplant recipients more than one year after a heart transplant. With this determination, Aetna joins the growing list of insurers that recognize the clinical effectiveness of AlloMap molecular expression testing.

Read at BioSpace.com

comments powered by Disqus
XDx, Inc.
Aetna
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES